Abstract

BackgroundMultipotent mesenchymal stromal cells (MSC) are well known for their multilineage potential and immunosuppressive properties. They might be a useful alternative for treatment of chronic inflammatory diseases. Little is known...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Azacitidine Directly Acts on the Mesenchymal Stromal Cell Compartment in Myelodysplastic Syndromes to Alter Niche Function and Suppress Malignant Hematopoeitic Stem/Progenitor Cells
Marie Weickert ... Julia Niggemeyer
Blood | VOL. 130
Marie Weickert, et. al.Marie Weickert ... Julia Niggemeyer
25 Jun 2021
Chd1 Regulates Primitive State of Bone Marrow Mesenchymal Stromal Cells without Affecting Hematopoietic Support; An Insight on the Dissociation Between Primitive State and Niche Function
Il-Hoan Oh ... Hyun-Kyung Choi
Blood | VOL. 124
Il-Hoan Oh, et. al.Il-Hoan Oh ... Hyun-Kyung Choi
06 Dec 2014
The scaffold protein Tks4 is required for the differentiation of mesenchymal stromal cells (MSCs) into adipogenic and osteogenic lineages.
Bálint Szeder ... Árpád Lányi
Scientific reports | VOL. 6
Bálint Szeder, et. al.Bálint Szeder ... Árpád Lányi
06 Oct 2016
Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells
Katrin Müller ... Marc Schmitz
Experimental Hematology | VOL. 40
Katrin Müller, et. al.Katrin Müller ... Marc Schmitz
31 Jul 2012
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers